10,000 Matching Annotations
  1. Oct 2026
    1. 32 F Type 2B VWD Type 2B Malmo/New York VWD c.3797C>T p.Pro1266Leu P

      Case 3: 32 y.o. female, study ID UZ002 in supplemental table

      DiseaseAssertion: type 2B VWD presequencing, type 2B Malmo/New York VWD postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: vWF:Ag (%) = 51; vWF:GPIbR (%) = 30; Act/Ag ratio = 0.59; FVIII:C (%) = 48; Platelets (x10^9/L) = 264

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod:WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3797C>T p.Pro1266Leu

      HGVS:

      ClinVarID: 314

      CAID:

      gnomAD: 0.0006678 (1077/1612852) 2 homozygotes https://gnomad.broadinstitute.org/variant/12-6019621-G-A?dataset=gnomad_r4

    2. 33 F Type 1 VWD Type 2M VWD c.3863T>G p.Leu1288Arg LP

      Case 2: 33 y.o. female, study ID UZ104 in supplemental table

      DiseaseAssertion: type 1 VWD presequencing, type 2M VWD postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: vWF:Ag (%) = 14; vWF:GPIbR (%) = 10; Act/Ag ratio = 1.00; FVIII:C (%) = 8; Platelets (x10^9/L) = 239

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3863T>G p.Leu1288Arg

      HGVS:

      ClinVarID: 100294

      CAID:

      gnomAD: absent

    3. 4 M Type 2 NOS VWD Type 2M VWD c.3863T>G p.Leu1288Arg LP

      Case 6: 4 y.o. male, study ID UZ024 in supplemental table

      DiseaseAssertion: type 2 NOS VWD presequencing; type 2M VWD postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 12.2; vWF:GPIbR (%) = 6.3; Act/Ag ratio = 0.52; FVIII:C (%) = 37.1; Platelets (x10^9/L) = 570

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3863T>G p.Leu1288Arg

      HGVS:

      ClinVarID: 100294

      CAID:

      gnomAD: absent

    4. Case UZ036: 13 year old female

      DiseaseAssertion: type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 6.5; vWF:GPIbR (%) = 4.6; Act/Ag ratio = 0.71; FVIII:C (%) = 28.6; Platelets (x10^9/L) = 258

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.8008G>A p.Gly2670Ser

      HGVS:

      ClinVarID: 1703812

      CAID:

      gnomAD: 0.000005576 (9 in 1614024) no homozygotes https://gnomad.broadinstitute.org/variant/12-5952498-C-T?dataset=gnomad_r4

      MultpleGeneVariants:

      Gene: FGG

      Variant: c.503C>T p.Thr168Met

      ClinVarID: 1703849

      gnomAD: 0.00003719 (60 in 1613552) no homozygotes https://gnomad.broadinstitute.org/variant/4-154610096-G-A?dataset=gnomad_r4

    5. 3 M Low VWF Low VWF c.7287+12T>G Splicing defect NA 0.03 0.00027 VUS

      Case 20: 3 year old male, study ID UZ067 in supplemental table

      DiseaseAssertion: low VWF

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 49; vWF:GPIbR (%) = 50.5; Act/Ag ratio = 1.03; FVIII:C (%) = 90.3; Platelets (x10^9/L) = 336

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod:WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.7287+12T>G p.?

      HGVS:

      ClinVarID: 2572109

      CAID:

      gnomAD: 0.000002479 (4 in 1613878) no homozygotes https://gnomad.broadinstitute.org/variant/12-5981774-A-C?dataset=gnomad_r4

    6. 2 F Type 2 NOS VWD Type 2B VWD + HA c.3946G>T p.Val1316Leu VUS

      Case 5: 2 y.o. female, study ID UZ068 in supplemental table

      DiseaseAssertion: type 2 NOS VWD presequencing, type 2B VWD + hemophilia A postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 43.3; vWF:GPIbR (%) = 25.2; Act/Ag ratio = 0.58; FVIII:C (%) = 21.6; Platelets (x10^9/L) = 384

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>T p.Val1316Leu

      HGVS:

      ClinVarID: 1703818

      CAID:

      gnomAD: 0.000001239 (2/1613946) 0 homozygotes https://gnomad.broadinstitute.org/variant/12-6019472-C-G?dataset=gnomad_r4

      MultipleGeneVariants: variant: F8:c.5883G>A; p.Trp1961*; ClinVar ID: 1703846

    7. 2 M Low VWF Low VWF c.5746C>G p.Arg1916Gly 0.21 0.00 0.00048 VUS

      Case 19: 2 year old male, study ID UZ070 in supplmental table

      DiseaseAssertion: low VWF

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 45; vWF:GPIbR (%) = 39.4; Act/Ag ratio = 0.88; FVIII:C (%) = 74.4; Platelets (x10^9/L) = 232

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod:WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.5746C>G p.Arg1916Gly

      HGVS:

      ClinVarID: 2572097

      CAID:

      gnomAD: 0.000004337 (7 in 1613868) no homozygotes https://gnomad.broadinstitute.org/variant/12-6011713-G-C?dataset=gnomad_r4

      MultipleSequenceVariants:

      Gene: SERPINC1

      Variant: c.89T>A p.Val30Glu

      ClinVarID: 18012

      gnomAD: 0.002625 (4237 in 1614198) 14 homozygotes https://gnomad.broadinstitute.org/variant/1-173914872-A-T?dataset=gnomad_r4

    8. Case UZ096: 38 year old female (row97 in supplemental table)

      DiseaseAssertion: type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 22.8; vWF:GPIbR (%) = 22; Act/Ag ratio = 0.96; FVIII:C (%) = 53.2; Platelets (x10^9/L) = 149

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.7636A>T p.Asn2546Tyr

      HGVS:

      ClinVarID: 100480

      CAID:

      gnomAD: 0.000003717 (6 in 1614024) no homozygotes https://gnomad.broadinstitute.org/variant/12-5969304-T-A?daset=gnomad_r4at

    9. 28 M Type 2 NOS VWD Type 2M VWD c.3943C>T p.Arg1315Cys P

      Case 10: 28 y.o. male, study ID UZ095 in Supplemental table

      DiseaseAssertion: Type 2 NOS VWD presequencing, type 2M VWD postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032441

      CaseHPOFreeRext: vWF:Ag (%) = 11.8; vWF:GPIbR (%) = 5; Act/Ag ratio = 0.42; FVIII:C (%) = 18.8; Platelets (x10^9/L) = 180

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1/1613892) 0 homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    10. Case UZ056: 8 year old male (row 57 in supplementary table)

      DiseaseAssertion: type 1/2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 10.8; vWF:GPIbR (%) = 9.6; Act/Ag ratio = 0.89; FVIII:C (%) = 30.2; Platelets (x10^9/L) = 196

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193).

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.5198T>C p.Leu1733Pro

      HGVS:

      ClinVarID: 1703810

      CAID:

      gnomAD: absent

    11. Case UZ050: 3 year old male (row 51 supplemental table)

      DiseaseAssertion: type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 29.6; vWF:GPIbR (%) = 26; Act/Ag ratio = 0.88; FVIII:C (%) = 78

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.6551G>A p.Cys2184Tyr

      HGVS:

      ClinVarID: 1677275

      CAID:

      gnomAD: 0.000001239 (2 in1613988) no homozygotes https://gnomad.broadinstitute.org/variant/12-5993909-C-T?dataset=gnomad_r4

    12. Case UZ098: 41 year old female (row 99 in supplemental table)

      DiseaseAssertion: type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 30.1; vWF:GPIbR (%) = 25.8; Act/Ag ratio = 0.86; FVIII:C (%) = 61.5; Platelets (x10^9/L) = 377

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4751A>G p.Tyr1584Cys

      HGVS:

      ClinVarID: 310

      CAID:

      gnomAD: 0.003442 (5555 in 1613678) 15 homozygotes https://gnomad.broadinstitute.org/variant/12-6018667-T-C?dataset=gnomad_r4

    13. Case UZ063: 10 year old male (row 64 supplemental table)

      DiseaseAssertion: type 2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442, HP:0040225

      CaseHPOFreeRext: vWF:Ag (%) = 20.2; vWF:GPIbR (%) = 8.5; Act/Ag ratio = 0.42; FVIII:C (%) = 28; Platelets (x10^9/L) = 242

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3863T>G p.Leu1288Arg

      HGVS:

      ClinVarID: 100294

      CAID:

      gnomAD: absent

    14. 47 F AVWS AVWS + type 1 VWD variant c.4751A>G p.Tyr1584Cys LP

      Case 17: 47 year old female, study ID UZ099 in supplemental table

      DiseaseAssertion: acquired VWD presequencing, acquired VWD + type 1 VWD variant postsequencing

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 2.6; vWF:GPIbR (%) = 2.2; Act/Ag ratio = 0.85; FVIII:C (%) = 7; Platelets (x10^9/L) = 325

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4751A>G p.Tyr1584Cys

      HGVS:

      ClinVarID: 310

      CAID:

      gnomAD: 0.003442 (5555 in 1613678) 15 homozygotes https://gnomad.broadinstitute.org/variant/12-6018667-T-C?dataset=gnomad_r4

      MultipleGeneVariants:

      FGG variant

      Variant: c.323C>G p.Ala108Gly

      ClinVarID: 547969

      gnomAD: 0.003031 (4885 in 1611606) 12 homozygotes https://gnomad.broadinstitute.org/variant/4-154611883-G-C?dataset=gnomad_r4

    15. 0 M Low VWF Low VWF c.4342C>T p.Gln1448∗ NA NA 0 LP

      Case 18: 0 year old male, study ID UZ078 in supplmental table

      DiseaseAssertion: low VWF

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370

      CaseHPOFreeRext: vWF:Ag (%) = 51.6; vWF:GPIbR (%) = 45.7; Act/Ag ratio = 0.89; FVIII:C (%) = 86.7; Platelets (x10^9/L) = 487

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4342C>T p.Gln1448*

      HGVS:

      ClinVarID: 2572655

      CAID:

      gnomAD: absent

    1. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25

      Case: IP #5 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 44; VWF:Ac [IU/dL] = 25; FVIII:C [IU/dL] = 135

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    2. 22, 23 c.4022G > A p.Arg1341Gln 28 A1 htz Missense A/O 42/32 17/15 51

      Case: IP #22 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 42; VWF:Ac [IU/dL] = 17; FVIII:C [IU/dL] = 51

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4022G>A p.Arg1341Gln

      HGVS:

      ClinVarID: 291

      CAID:

      gnomAD: 0.000001239 (2 in 1613944) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019396-C-T?dataset=gnomad_r4

    3. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88/76

      Case: IP #16 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 93; VWF:Ac [IU/dL] = 48; FVIII:C [IU/dL] = 76

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    4. 16–21 c.3946G > A p.Val1316Met C 28 A1 htz Missense B/O/A/na/A/na63/62/25/58/48/3610/22 RCo /6/22/11/982 CSA /37/26

      Case: IP #18 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 25; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>A p.Val1316Met

      HGVS:

      ClinVarID: 290

      CAID:

      gnomAD: absent

    5. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25/5/6/837

      Case: IP #2 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 21; VWF:Ac [IU/dL] = 13; FVIII:C [IU/dL] = 37

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    6. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88/76/na/53 CSA /11 CSA /23 CSA /53

      Case: IP #21 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 22; VWF:Ac [IU/dL] = 26; FVIII:C [IU/dL] = 53

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    7. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426 CSA /39/28 OSCA /na /26 CSA /26 CSA /22 CSA /12

      Case: IP #20 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 10; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 12

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    8. 6–8 U (2A/1) c.3437A > G p.Tyr1146Cys 26 D3-TIL3 htz Missense A/na/na 17/17/17 17/35/26 22

      Case: IP #6 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/1) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 17; FVIII:C [IU/dL] = 22

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3437A>G p.Tyr1146Cys

      HGVS:

      ClinVarID: 31009

      CAID:

      gnomAD: 0.000001840 (1 in 543518) no homozygotes https://gnomad.broadinstitute.org/variant/12-6022841-T-C?dataset=gnomad_r4

    9. 8–10 2N c.2446C > Tc.2561G > Ap.Arg816Trpp.Arg854Gln1920D’-TIL’D’-E’htzhtzMissenseMissenseA/A/na 61/93/50 59/107/55 25

      Case: IP #8 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 61; VWF:Ac [IU/dL] = 59; FVIII:C [IU/dL] = 25

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2446C > T p.Arg816Trp

      HGVS:

      ClinVarID: 295

      CAID:

      gnomAD: 0.00001983 (32 in 1613930) no homozygotes https://gnomad.broadinstitute.org/variant/12-6036488-G-A?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      ClinVar: 296

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    10. 36 Type2A(IIA)c.4541T>G p.Phe1514Cys 28 A2 htz Missense O 40 16 51

      Case: IP #36

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 40; VWF:Ac [IU/dL] = 16; FVIII:C [IU/dL] = 51

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4541T>G p.Phe1514Cys

      HGVS:

      ClinVarID: 304

      CAID:

      gnomAD: absent

    11. 18-20Type2A (IIE)c.3437A>G p.Tyr1146Cys 26 D3-TIL-3htz Missense na/A/A19.3/12/299/5/18 30

      Case: IP #18

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 19.3; VWF:Ac [IU/dL] = 9; FVIII:C [IU/dL] = 30

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3437A>G p.Tyr1146Cys

      HGVS:

      ClinVarID: 31009

      CAID:

      gnomAD: 0.000001840 (1 in 543518) no homozygotes https://gnomad.broadinstitute.org/variant/12-6022841-T-C?dataset=gnomad_r4

    12. 11–13 2N c.2561G > A p.Arg854Gln 20 D’-E’ hmz Missense O/O/na 74/59/55 79/59/45 18

      Case: IP #11 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 74; VWF:Ac [IU/dL] = 79; FVIII:C [IU/dL] = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    13. 1 U c.2435delc.3797C > Tp.Pro812Argfs31p.Pro1266Leu C1828D’TIL’D3-E3htzhtzSmall Del.Missensena 17 13 GPIbR 49

      Case: IP #1 in type U VWD sub-cohort

      DiseaseAssertion: unclassified VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 13; FVIII:C [IU/dL] = 49

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2435del p.Pro812Argfs*31

      HGVS:

      ClinVarID: 303

      CAID:

      gnomAD: 0.00007187 (116 in 1613916) no homozygotes https://gnomad.broadinstitute.org/variant/12-6044297-CG-C?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3797C>T p.Pro1266Leu

      ClinVarID: 314

      gnomAD: 0.0006678 (1077 in 1612852) 2 homozyogotes https://gnomad.broadinstitute.org/variant/12-6019621-G-A?dataset=gnomad_r4

    14. 43-49Type2A(IIA)c.4789C>T p.Arg1597Trp 28 A2 htz Missense A/na/A/O/B/na/O22/30/26/64/24/16/5613/11RCo/9/16/6/6/1529/47/30CSA/66CSA/32CSA/20CSA/47

      Case: IP #49

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 56; VWF:Ac [IU/dL] = 15; FVIII:C [IU/dL] = 47

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4789C>T p.Arg1597Trp

      HGVS:

      ClinVarID: 285

      CAID:

      gnomAD: 6.196e-7 (1 in 1614028) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018629-G-A?dataset=gnomad_r4

    15. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426 CSA /39

      Case: IP #14 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 20; VWF:Ac [IU/dL] = 13; FVIII:C [IU/dL] = 39

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    16. 43-49Type2A(IIA)c.4789C>T p.Arg1597Trp 28 A2 htz Missense A/na/A/O/B/na/O22/30/26/64/24/16/5613/11RCo/9/16/6/6/1529/47/30

      Case: IP #45

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 26; VWF:Ac [IU/dL] = 9; FVIII:C [IU/dL] = 30

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4789C>T p.Arg1597Trp

      HGVS:

      ClinVarID: 285

      CAID:

      gnomAD: 6.196e-7 (1 in 1614028) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018629-G-A?dataset=gnomad_r4

    17. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426 CSA /39/28 OSCA /na /26

      Case: IP #17 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032441 - blood group AB

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 12; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    18. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426 CSA /39/28 OSCA /na /26 CSA /26 CSA /22

      Case: IP #19 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 13; VWF:Ac [IU/dL] = 8; FVIII:C [IU/dL] = 22

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    19. 18-20Type2A (IIE)c.3437A>G p.Tyr1146Cys 26 D3-TIL-3htz Missense na/A/A19.3/12/299/5/18 30/24CSA/na

      Case: IP #20

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 29; VWF:Ac [IU/dL] = 18; FVIII:C [IU/dL] = n/a

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3437A>G

      HGVS:

      ClinVarID: 31009

      CAID:

      gnomAD: 0.000001840 (1 in 543518) no homozygotes https://gnomad.broadinstitute.org/variant/12-6022841-T-C?dataset=gnomad_r4

    20. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88/76/na/53

      Case: IP #18 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 151; VWF:Ac [IU/dL] = 121; FVIII:C [IU/dL] = 53

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    21. 12–14 c.3922C > T p.Arg1308Cys C 28 A1 htz Missense na /AB/A 42/30/14 15 RCo /6/10 48/41 CSA /26

      Case: IP #14 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 14; VWF:Ac [IU/dL] = 10; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3922C>T p.Arg1308Cys

      HGVS:

      ClinVarID: 289

      CAID:

      gnomAD: absent

    22. 5, 6 2N/1 c.2435delc.2561G > Ap.Pro812Argfs31p.Arg854Gln1820D’-TIL’D’-E’htzhtzSmall Del.Missensena/na 29/74 26/80 10

      Case: IP #5 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 29; VWF:Ac [IU/dL] = 26; FVIII:C [IU/dL] = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2435del p.Pro812Argfs*31

      HGVS:

      ClinVarID: 303

      CAID:

      gnomAD: 0.00007187 (116 in 1613916) no homozygotes https://gnomad.broadinstitute.org/variant/12-6044297-CG-C?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variants: c.2561G>A p.Arg854Gln

      ClinVarID: 296

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    23. 9 U c.3437A > Gc.3539–10T > G Np.Tyr1146Cys-2625D3-TIL-3D3-TIL-3htzhtzMissenseSplice SiteO 12 10 21

      Case: IP #9 in type U VWD sub-cohort

      DiseaseAssertion: unclassified VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 12; VWF:Ac [IU/dL] = 10; FVIII:C [IU/dL] = 21

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3437A>G p.Tyr1146Cys

      HGVS:

      ClinVarID: 31009

      CAID:

      gnomAD: 0.000001840 (1 in 543518) no homozygotes https://gnomad.broadinstitute.org/variant/12-6022841-T-C?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3539–10T>G

      ClinVarID: not found

      **gnomAD: absent

    24. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88

      Case: IP #15 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 67; VWF:Ac [IU/dL] = 78; FVIII:C [IU/dL] = 88

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    25. 59-62Type2A(IIA)c.4883T>C p.Ile1628Thr 28 A2 htz Missense na/A/O/na28.7/38/17/555/7/5/932/37

      Case: IP #60

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 38; VWF:Ac [IU/dL] = 7; FVIII:C [IU/dL] = 37

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4883T>C p.Ile1628Thr

      HGVS:

      ClinVarID: 284

      CAID:

      gnomAD: 0.000001859 (3 in 1613848) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018535-A-G?dataset=gnomad_r4

    26. 23 2N/1 c.2561G > Ac.4751A > Gp.Arg854Glnp.Tyr1584Cys2028D’-E’A2htzhtzMissenseMissenseA 40 54 GPIbR 50

      Case: IP #23 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N/1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 40; VWF:Ac [IU/dL] = 54; FVIII:C [IU/dL] = 50

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.4751A>G p.Tyr1584Cys

      ClinVarID: 310

      gnomAD: 0.003442 (5555 in 1613678) 15 homozygotes https://gnomad.broadinstitute.org/variant/12-6018667-T-C?dataset=gnomad_r4

    27. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88/76/na/53 CSA /11 CSA /23

      Case: IP #20 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 49; VWF:Ac [IU/dL] = 41; FVIII:C [IU/dL] = 23

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    28. 16–21 c.3946G > A p.Val1316Met C 28 A1 htz Missense B/O/A/na/A/na63/62/25/58/48/3610/22 RCo /6/22/11/982 CSA /37

      Case: IP #17 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 62; VWF:Ac [IU/dL] = 22; FVIII:C [IU/dL] = 37

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>A p.Val1316Met

      HGVS:

      ClinVarID: 290

      CAID:

      gnomAD: absent

    29. 3 c.4001G > A p.Arg1334Gln 28 A1 htz Missense 41na44 na na na

      Case: IP #3 in type 2M VWD sub-cohort

      DiseaseAssertion: type 2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 41na44; VWF:Ac [IU/dL] = n/a; FVIII:C [IU/dL] = n/a; VWF:CB (IU/dL) = n/a

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4001G>A p.Arg1334Gln

      HGVS:

      ClinVarID: 2572701

      CAID:

      gnomAD: 0.000006196 (10 in 1613834) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019417-C-T?dataset=gnomad_r4

    30. 25 2N/HemophiliaAc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense A 121 111 RCo 1

      Case: IP #25 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD and hemophilia A

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 121; VWF:Ac [IU/dL] = 111; FVIII:C [IU/dL] = 1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    31. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426

      Case: IP #13 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 12; VWF:Ac [IU/dL] = 7; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    32. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656

      Case: IP #14 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 55; VWF:Ac [IU/dL] = 30; FVIII:C [IU/dL] = 56

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    33. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25/5/6/837/na/46/135 CSA /27 CSA /20 CSA /33

      Case: IP #8 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 27; VWF:Ac [IU/dL] = 8; FVIII:C [IU/dL] = 33

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    34. 13–21 U (2A/2M/1C) c.3943C > T p.Arg1315Cys C 28 A1 htz Missense A/O/A/na/AB/A/O/A/A12/20/20/40/12/17/13/10 /147/13 RCo /15/10/6/14/8/6/426 CSA /39/28 OSCA /na /26 CSA /26

      Case: IP #18 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 14; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      HGVS:

      ClinVarID: 100310

      CAID:

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    35. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25/5/6/837/na/46

      Case: IP #4 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 48; VWF:Ac [IU/dL] = 33; FVIII:C [IU/dL] = 46

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    36. 43-49Type2A(IIA)c.4789C>T p.Arg1597Trp 28 A2 htz Missense A/na/A/O/B/na/O22/30/26/64/24/16/5613/11RCo/9/16/6/6/1529/47/30CSA/66CSA/32CSA/20

      Case: IP #48

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 16; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4789C>T p.Arg1597Trp

      HGVS:

      ClinVarID: 285

      CAID:

      gnomAD: 6.196e-7 (1 in 1614028) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018629-G-A?dataset=gnomad_r4

    37. 43-49Type2A(IIA)c.4789C>T p.Arg1597Trp 28 A2 htz Missense A/na/A/O/B/na/O22/30/26/64/24/16/5613/11RCo/9/16/6/6/1529/47

      Case: IP #44

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 30; VWF:Ac [IU/dL] = 11; FVIII:C [IU/dL] = 47

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4789C>T p.Arg1597Trp

      HGVS:

      ClinVarID: 285

      CAID:

      gnomAD: 6.196e-7 (1 in 1614028) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018629-G-A?dataset=gnomad_r4

    38. 59-62Type2A(IIA)c.4883T>C p.Ile1628Thr 28 A2 htz Missense na/A/O/na28.7/38/17/555/7/5/932

      Case: IP #59

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 28.7; VWF:Ac [IU/dL] = 5; FVIII:C [IU/dL] = 32

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4883T>C p.Ile1628Thr

      HGVS:

      ClinVarID: 284

      CAID:

      gnomAD: 0.000001859 (3 in 1613848) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018535-A-G?dataset=gnomad_r4

    39. 21 c.3946G > A p.Val1316Met C 28 A1 htz Missense B/O/A/na/A/na63/62/25/58/48/3610/22 RCo /6/22/11/982 CSA /37/26/54/46 CSA /36

      Case: IP #21 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 36; VWF:Ac [IU/dL] = 9; FVIII:C [IU/dL] = 36

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>A p.Val1316Met

      HGVS:

      ClinVarID: 290

      CAID:

      gnomAD: absent

    40. 14–21 Heterozygous2Nc.2561G > A p.Arg854Gln 20 D’-E’ htz Missense O/O/na/na /A/A/O/B55/67/93/46/151/45/49 /2230 Rco / 78 GPIbR /48/64/121/42/41/2656 OSCA /88/76/na/53 CSA /11

      Case: IP #19 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 45; VWF:Ac [IU/dL] = 42; FVIII:C [IU/dL] = 11

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    41. 12–14 c.3922C > T p.Arg1308Cys C 28 A1 htz Missense na /AB/A 42/30/14 15 RCo /6/10 48/41

      Case: IP #13 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032441 - blood group AB

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 30; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3922C>T p.Arg1308Cys

      HGVS:

      ClinVarID: 289

      CAID:

      gnomAD: absent

    42. 16–21 c.3946G > A p.Val1316Met C 28 A1 htz Missense B/O/A/na/A/na63/62/25/58/48/3610/22 RCo /6/22/11/982

      Case: IP #16 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 63; VWF:Ac [IU/dL] = 10; FVIII:C [IU/dL] = 82

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>A p.Val1316Met

      HGVS:

      ClinVarID: 290

      CAID:

      gnomAD: absent

    43. 18-20Type2A (IIE)c.3437A>G p.Tyr1146Cys 26 D3-TIL-3htz Missense na/A/A19.3/12/299/5/18 30/24

      Case: IP #19

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 12; VWF:Ac [IU/dL] = 5; FVIII:C [IU/dL] = 24

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3437A>G

      HGVS:

      ClinVarID: 31009

      CAID:

      gnomAD: 0.000001840 (1 in 543518) no homozygotes https://gnomad.broadinstitute.org/variant/12-6022841-T-C?dataset=gnomad_r4

    44. 1 c.2561G > Ac.3916C > Tp.Arg854Glnp.Arg1306Trp C2028D’-E’A1htz MissenseMissenseA 17 4 26

      Case: IP #1 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 4; FVIII:C [IU/dL] = 26

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      ClinVarID: 288

      gnomAD: absent

    45. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25/5/6/837/na/46/135 CSA /27 CSA /20

      Case: IP #7 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 22; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    46. 16–21 c.3946G > A p.Val1316Met C 28 A1 htz Missense B/O/A/na/A/na63/62/25/58/48/3610/22 RCo /6/22/11/982 CSA /37/26/54/46

      Case: IP #20 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 48; VWF:Ac [IU/dL] = 11; FVIII:C [IU/dL] = 46

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3946G>A p.Val1316Met

      HGVS:

      ClinVarID: 290

      CAID:

      gnomAD: absent

    47. 7 2N c.2446C > T p.Arg816Trp 19 D’TIL’ hmz Missense B 166 144 2

      Case: IP #7 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 166; VWF:Ac [IU/dL] = 144; FVIII:C [IU/dL] = 2

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2446C>T p.Arg816Trp

      HGVS:

      ClinVarID: 295

      CAID:

      gnomAD: 0.00001983 (32 in 1613930) no homozygotes https://gnomad.broadinstitute.org/variant/12-6036488-G-A?dataset=gnomad_r4

    48. 12–14 c.3922C > T p.Arg1308Cys C 28 A1 htz Missense na /AB/A 42/30/14 15 RCo /6/10 48

      Case: IP #12 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 42; VWF:Ac [IU/dL] = 15; FVIII:C [IU/dL] = 48

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3922C>T p.Arg1308Cys

      HGVS:

      ClinVarID: 289

      CAID:

      gnomAD: absent

    49. 5, 6 2N/1 c.2435delc.2561G > Ap.Pro812Argfs31p.Arg854Gln1820D’-TIL’D’-E’htzhtzSmall Del.Missensena/na 29/74 26/80 10 CSA /40

      Case: IP #6 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 74; VWF:Ac [IU/dL] = 80; FVIII:C [IU/dL] = 40

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2435del p.Pro812Argfs*31

      HGVS:

      ClinVarID: 303

      CAID:

      gnomAD: 0.00007187 (116 of 1613916) no homozygotes https://gnomad.broadinstitute.org/variant/12-6044297-CG-C?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      ClinVarID: 296

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    50. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na

      Case: IP #3 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 37; VWF:Ac [IU/dL] = n/a; FVIII:C [IU/dL] = n/a

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    51. 11–13 2N c.2561G > A p.Arg854Gln 20 D’-E’ hmz Missense O/O/na 74/59/55 79/59/45 18/16/16

      Case: IP #13 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 55; VWF:Ac [IU/dL] = 45; FVIII:C [IU/dL] = 16

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      HGVS:

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    52. 2–8 c.3916C > T p.Arg1306Trp C 28 A1 htz Missense A/na/O/B/O/O/A21/37/48/44/22/22/2713 RCo /na/33/25/5/6/837/na/46/135 CSA /27

      Case: IP #6 in type 2B VWD sub-cohort

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 22; VWF:Ac [IU/dL] = 5; FVIII:C [IU/dL] = 27

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3916C>T p.Arg1306Trp

      HGVS:

      ClinVarID: 288

      CAID:

      gnomAD: absent

    53. 43-49Type2A(IIA)c.4789C>T p.Arg1597Trp 28 A2 htz Missense A/na/A/O/B/na/O22/30/26/64/24/16/5613/11RCo/9/16/6/6/1529/47/30CSA/66CSA/32

      Case: IP #47

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 24; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 32

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4789C>T p.Arg1597Trp

      HGVS:

      ClinVarID: 285

      CAID:

      gnomAD: 6.196e-7 (1 in 1614028) no homozygotes https://gnomad.broadinstitute.org/variant/12-6018629-G-A?dataset=gnomad_r4

    54. 8–10 2N c.2446C > Tc.2561G > Ap.Arg816Trpp.Arg854Gln1920D’-TIL’D’-E’htzhtzMissenseMissenseA/A/na 61/93/50 59/107/55 25 CSA /18 CSA /15

      Case: IP #10 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 50; VWF:Ac [IU/dL] = 55; FVIII:C [IU/dL] = 15

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2446C > T p.Arg816Trp

      HGVS:

      ClinVarID: 295

      CAID:

      gnomAD: 0.00001983 (32 in 1613930) no homozygotes https://gnomad.broadinstitute.org/variant/12-6036488-G-A?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      ClinVar: 296

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    55. 50 Type2A(IIA)c.4790G>A p.Arg1597Gln 28 A2 htz Missense na na 11 na

      Case: IP #50

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = n/a; VWF:Ac [IU/dL] = 11; FVIII:C [IU/dL] = n/a

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4790G>A p.Arg1597Gln

      HGVS:

      ClinVarID: 100391

      CAID:

      gnomAD: absent

    1. Case: Row 21 in Supplemental Table 1. Variant is found in 14 patients in 13 families

      DiseaseAssertion: 10 have type 1 VWD, 2 have VWD type 2A, 2 have VWD type 2M

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 1.2 (1.1-1.4); VWFpp/VWF:Ag = 2.0 (1.2-2.9)

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: 2771G>A R924Q

      HGVS: VWF:c.2561G>A p.Arg854Gln

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: Type 1: two also had C2304Y and one had T1156M. 2M: one also had R1374H. 2A: one also had G1609R

    2. Case: Row 2 in Supplemental Table 1. Represents 13 patients in 13 families.

      DiseaseAssertion: 13 type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 3.0 (1.7-4.0); VWFpp/VWF:Ag = 1.9 (1.5-2.9)

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: Del exon 4-5

      HGVS: c.221-977_532+7059del

      ClinVarID: 156329

      CAID:

      gnomAD: absent

    3. Case: Row 8 in Supplemental Table 1.

      DiseaseAssertion: type 3 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 10.0; VWFpp/VWF:Ag = 1.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: 1543_1544insGGACAGCT V515G fs*65

      HGVS: c.1543_1544insGGACAGCT (p.Val515Glyfs*65)

      ClinVarID: 1695359

      CAID:

      gnomAD: absent

    4. Case: Row 16 in Supplemental Table 1.

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 0.2; VWFpp/VWF:Ag = 2.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: 2372C>T T791M

      HGVS: VWF:c.2372C>T p.Thr791Met

      ClinVarID: 294

      CAID:

      gnomAD: 0.00001797 (29 in 1614030) no homozygotes https://gnomad.broadinstitute.org/variant/12-6044361-G-A?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: P812R fs*31

    5. Case: Row 20 in Supplemental Table 1. Variant is found in 14 patients in 14 families

      DiseaseAssertion: 7 have type 1 VWD, 7 have VWD type 2N

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 1.2 (0.4-1.9); VWFpp/VWF:Ag = 2.7 (1.6-3.8)

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: 2561G>A R854Q

      HGVS: VWF:c.2561G>A p.Arg854Gln

      ClinVarID: 296

      CAID:

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: Type 2N; Three also had R2535, one N2546Y, one 6257-1G>A (novel), and one H1419M fs22 (novel). Type 1: one also had S1090_C1099del (novel) and one had del exon 33-34

    6. Case: Row 17 in Supplemental Table 1. Found in 2 patients in the same family.

      DiseaseAssertion: type 1 VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: FVIII:C/VWF:Ag = 2.3 (1.7-3.2); VWFpp/VWF:Ag = 3.0 (2.9-3.2)

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Genetic analysis was performed at the laboratory of hematology of the Radboud University Medical Center in Nijmegen. Ion semiconductor sequencing (Ion-Torrent) was used to analyze the VWF gene from peripheral blood obtained in EDTA tubes or from saliva samples. The 52 exons of VWF gene were analyzed including ±20 bp exon-intron boundaries. If no VWF gene variant was detected, multiplex ligation-dependent probe amplification (MLPA) analysis was performed to find large deletions or duplications. Thus, MLPA was performed in 183 patients (46.9%). All variants were confirmed with Sanger sequencing.

      PreviouslyPublished:

      Gene: VWF

      Variant: 2435delC P812R fs*31

      HGVS: VWF:c.2435del p.Pro812Argfs*31

      ClinVarID: 303

      CAID:

      gnomAD: 0.00007187 (116 in 1613916) no homozygotes https://gnomad.broadinstitute.org/variant/12-6044297-CG-C?dataset=gnomad_r4

    1. 21-year-old professional soccer player

      Case1: 21, Male

      DiseaseAssertion: To be found

      FamilyInfo: No remarkable family history.

      CasePresentingHPOs: HP:0003401, HP:0410173, HP:0001688

      CaseHPOFreeText: "arietal ischemic lesions, elevated high-sensitivity I troponin, left ventricle (LV) dilation, apical hypokinesia, apical thrombus, and multifocal nonischemic late gadolinium enhancement with edema" " elevated N-terminal pro–B-type natriuretic peptide and low c-reactive protein"

      CaseNotHPOs: HP:0001297, HP:0012819

      CaseNotHPOFreeText: "A cardioembolic stroke due to myocarditis with an LV thrombus was assumed" “Ischemic heart disease was considered unlikely at presentation” “Cardiac sarcoidosis was considered but was not supported” “Autoimmune myocarditis and other systemic inflammatory causes were also considered” “Giant cell myocarditis was considered to be unlikely”

      CasePreviousTesting:

      Genotyping Method: Whole genome sequencing

      Variant: c.1484G>A; p.Arg495Gln

      ClinVar: CA010464

      gnomAD: To be found

    1. proband is a 44-year old male of European

      Case1: A 44-year old male of European (non-Finnish) ancestry.

      DiseaseAssertion: Disease, with the MYL2 p.Ala13Thr variant.

      FamilyInfo: Mother, father, and sister was diagnosed at different ages; they all had it.

      ParentalTesting: Yes with screening by ECG and Echocardiography; underwent 12-lead electrocardiography (ECG), echocardiography (M-mode, 2D, and Doppler), and cardiac magnetic resonance imaging (CMR).

      CasePresentingHPOs:HP:0100749, HP:0002094, HP:0031664, HP:0033678, HP:0011703, HP:0001712, HP:0031296,HP:0020034, HP:0031656

      CaseHPOFreeText: Presented 3 years ago with persistent but mild chest pain and dyspnea. presence of II/VI mid-systolic murmur that increased with the Valsalva maneuver. Cardiac enzymes were negative for acute coronary syndromes. A 12-lead ECG was notable for sinus tachycardia at the rate of 104 bpm and evidence of left ventricular hypertrophy (LVH) with repolarization abnormalities. Myocardial stress perfusion tomography showed homogeneous distribution of the radiotracer in the myocardium. An echocardiogram showed a hyperdynamic left ventricle with moderate asymmetric septal hypertrophy, a maximum wall thickness of 1.8 cm. There was a resting left ventricular outflow tract (LVOT) gradient of 20 mmHg that increased to 40 mmHg upon Valsalva maneuver. CMR findings were notable for septal hypertrophy and diffuse patchy hyperenhancement, involving multiple myocardial walls. increasing dyspnea with a mild level of physical activity and chest pain. Evidence of LVH with repolarization abnormalities on a 12-lead ECG and a hyperdynamic left ventricle with a septal thickness of 2 cm, systolic anterior motion of mitral leaflets, mild to moderate mitral regurgitation, and an LVOT gradient of 100 mmHg on echocardiography (Figure 3A). Underwent surgical myectomy, which led to resolution of LVOT gradient and symptoms.

      CaseNotHPOs: HP:0011675, HP:0011703

      CaseNotHPOFreeText: Not show significant cardiac arrhythmias except for periods of sinus tachycardia at rest.

      CasePreviousTesting: Whole exome sequencing (WES)

      Genotyping Method: Sanger sequencing

      FunctionalAnalysis: May affect cardiac contractile function and actin filament velocity, But NR about the MYL2 p.Ala13Thr variant.

      Variant: NM_000432.4:c.37G>A

      ClinVar:14064

      CAID: CA010242

      gnomAD: gnomAD v2 12:111356964 C / T , gnomAD v3 12:110919160 C / T gmonAD v4 chr12-110919160-C-T

      AdditionalInfo: NR

    1. Family M1

      Case1: A 68-year-old female

      DiseaseAssertion: dilated cardiomyopathy (DCM), with the MYH7 p.Lys637Glu (K637E) variant identified in the affected patient. The study investigated sarcomeric gene variants associated with DCM

      FamilyInfo: The proband's father (M1, II:3) died suddenly at 36 years of age, 2 years after being diagnosed with DCM.

      ParentalTesting: Yes from father

      CasePresentingHPOs: HP:0011664, HP:0011713, HP:0003677, HP:0001635,

      CaseHPOFreeText: was diagnosed as having left ventricular non-compaction (LVNC) based on echocardiography. A left bundle branch block on her ECG. Echocardiography revealed LVNC and she has had a slow progression towards heart failure and an increasing dilatation of her left ventricle. Age 48 at onset, left ventricular end diastolic diameter 59 mm, left ventricular ejection fraction 25%, ventricular extrasystoles for arrhythmia.

      CaseNotHPOs:NR

      CaseNotHPOFreeText:NR

      CasePreviousTesting:NR

      Genotyping Method: genetically screened, also using GenBank with PCR by amplifying the coding region

      FunctionalAnalysis:NR

      Variant: NM_000257.4:c.1909A>G

      ClinVar: 1329402

      CAID:CA389049558

      gnomAD: NR

      AdditionalInfo: NR

    1. CasePT-104: United States

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy)

      HPOsFreeText: N/A

      CaseNotHPOs: HP:0001650, HP:0001658 (Aortic valve stenosis, Myocardial infarction)

      NotHPOsFreeText: N/A

      CaseAddInfo:


      CaseGenotypingMethod: DNA was collected from the participants using blood samples. 18 genes suspected on contributing to HCM were targeted and sequenced. The variants were then located and filtered for pathogenicity.


      Variant: NM_000257.3:c.4399C>G (p.Leu1467Val)

      ClinVar: 43015 https://www.ncbi.nlm.nih.gov/clinvar/variation/43015/

      gnomAD: South Asian 1.111e-3, Overall 1.352e-4 https://gnomad.broadinstitute.org/variant/14-23886482-G-C

    1. 1

      Case1: Male, 0.5 yr onset, 2.5 yr diagnosis, 10.04 yr report

      CasePresentingHPOs: HP:0001371 (Contractures)

      HPOsFreeText: Wheelchair used, FVC z-score sitting -0.25 (97% pred), FVC z-score supine -1.12 (87% pred), 65% MRC Scale, 530 CK U/l, 9.1 GAA activity (nmol/h/mg)^h from cultured fibroblasts

      NotHPOsFreeText: No respiratory support

    2. 7

      Case7: Male, 1 yr onset, 2 yr diagnosis, 13.7 yr report

      CasePresentingHPOs: HP:0002650 (Scoliosis)

      HPOsFreeText: Respiratory support at night, FVC z-score sitting -4.08 (54% pred), FVC z-score supine -5.4 (39% pred), 87% MRC Scale, 548 CK U/l, 17.9 GAA activity (nmol/h/mg)^h from cultured fibroblasts

      NotHPOsFreeText: No wheelchair used

    1. Patient 5

      Case5: Female, Caucasian, United States, 2 months onset and diagnosis, 0.4 years report

      CasePresentingHPOs: HP:0011968, HP:0011469, HP:0012378, HP:0004347, HP:0010453 (Feeding difficulties, Nasal regurgitation, Fatigue, Weakness of muscles of respiration, Pelvic bone asymmetry)

      HPOsFreeText: Difficulty in lying supine while eating, sleeping and self-limited gasping episodes was observed, PT evaluation showed mild consistent asymmetry with increased lateral head tilt to the right, Tendency towards flexion/abduction/external rotation positioning of lower extremities was noted, Slight lateral thigh grooves reflected early IT band tightness with decreased posterior weight shift and propping on forearms in prone, AIMS score was at 10th percentile for chronological age and 25th to 50th percentile for corrected age, ALT 27 U/L (Normal 5–40 U/L), AST 36 U/L (Normal 15–41 U/L), ALP 352 U/L (Normal 24–170 U/L), Urinary Glc4 4.1 mmol/mol creatinine (Normal ≤8.3 mmol/mol creatinine)

      CaseNotHPOs: HP:0002033, HP:0002015, HP:0004323, HP:0003808 (Poor suck, Poor swallowing, Abnormality of body weight, Abnormal muscle tone)

      NotHPOsFreeText: CK levels, ECG, and ECHO have consistently been within normal limits, Had normal passive ranges of motion and appropriate weight bearing through lower extremities in supported standing

    2. Patient 4

      Case4: Female, Caucasian, United States, 1 month onset, 6 months diagnosis, 1.1 years report

      CasePresentingHPOs: HP:0003236, HP:0012378, HP:0006589, HP:0003725 (Increased serum CK, Fatigue, Flaring of lower rib cage, Firm muscles)

      HPOsFreeText: HyperCKemia present in the first month (505 IU/L; Normal 30–279 IU/L) but normalized spontaneously at 4 months (188 IU/L), PT assessment revealed subtle motor signs including preferred position of ring sitting with hips in flexion/abduction/external rotation and bilateral IT band tightness, Imbalanced trunk flexion, Decreased use of abdominals and excessive use of spinal extension, Asymmetry was noted in reaching objects in prone and weight shifting with lateral flexion and shortening on the left at the neck and trunk, AIMS score was at the 25th percentile and GMFM was 22.14%, Urinary Glc4 4.8 mmol/mol creatinine (Normal ≤8.3 mmol/mol creatinine)

      CaseNotHPOs: HP:0003690 (Limb muscle weakness)

      NotHPOsFreeText: She had no head lag when pulled to sit and the ability to transfer objects and bring them to midline

    3. Patient 1

      Case1: Male, Caucasian, United States, Birth onset

      CasePresentingHPOs: HP:0008872, HP:0002100, HP:0001508, HP:0008947, HP:0001655, HP:0003236, HP:0200136, HP:0001290, HP:0002835, HP:0002194 (Feeding difficulties in infancy, Recurrent aspiration pneumonia, Poor weight gain, Infantile muscular hypotonia, Patent foramen ovale, Increased serum CK, Oropharyngeal dysphagia, Low muscle tone, Aspiration, Delayed gross motor development)

      HPOsFreeText: HyperCKemia was present since the early neonatal period (378 IU/L, day 8 of life; N: 60–305 IU/L), ERT at a dose of 20 mg/kg every 2 weeks was initiated at age 1 month, CK levels were normalized on ERT by age 4 months (80 IU/L), Flexion/abduction/ external rotation positioning of lower extremities, iliotibial (IT) band tightness, lack of independent sitting, AIMS score between 10th and 25th percentile, GMFM at 23.16%, At age 23 months, he had achieved significant motor milestones; started sitting with support at 10 months and without support at 12 months, pulled to stand at 12 months, walked at 15 months and could feed himself with an immature pincer grasp. Swallow study was normal, ALT 26 U/L (Normal 5–40 U/L), AST 45 U/L (Normal 15–41 U/L), ALP 211 U/L (Normal 24–170 U/L), Urinary Glc4 3.7 mmol/mol creatinine (Normal ≤8.3 mmol/mol creatinine)

      CaseNotHPOs: HP:0011675, HP:0002910 (ECG abnormality, Elevated hepatic transaminases)

      NotHPOsFreetext:

      CaseAddInfo: Older brother of Patient 2, Late-Onset Pompe Disease

    4. Patient 2

      Case2: Male, Caucasian, United States, Birth onset

      CasePresentingHPOs: HP:0001290, HP:0200136, HP:0002033, HP:0003236, HP:0001655, HP:0002058, HP:0002194, HP:0002421, HP:0000467, HP:0002015 (Generalized hypotonia, Oral-pharyngeal dysphagia, Poor suck, Increased serum CK, Patent foramen ovale, Myopathic face, Delayed gross motor development, Poor head control, Neck muscle weakness, Dysphagia)

      HPOsFreeText: hyperCKemia at 435 IU/L on day of life 4, Patent foramen ovale detected at birth by ECHO but resolved spontaneously, PT evaluation at age 2 months revealed flexion/abduction/external rotation positioning of lower extremities with tightness bilaterally in hip flexors, hamstrings, and IT bands, Had a tendency to remain on toes when held in supported standing with additional support required for weight bearing through lower extremities, Had difficulty lifting his head in prone, with asymmetric head lift to 45 degrees, and an inability to maintain head in midline when supine, AIMS score at age 2 months was between 10–25th percentile, ALT 41 U/L (Normal 5–40 U/L), AST 33 U/L (Normal 15–41 U/L), ALP 239 U/L (Normal 24–170 U/L), Urinary Glc4 4.5 mmol/mol creatinine (Normal ≤8.3 mmol/mol creatinine)

      CaseNotHPOs: HP:0011016 (Abnormality of urine glucose concentration)

      NotHPOsFreeText:

      CaseAddInfo: Younger brother of Patient 1, Late-Onset Pompe Disease

    5. Patient 7

      Case7: Female, Caucasian, United States, 6 months diagnosis, 8 months report

      CasePresentingHPOs: HP:0001643, HP:0006699, HP:0006682, HP:0003722, HP:0008969 (Patent ductus arteriosus, Premature atrial contractions, Premature ventricular contractions, Neck flexor weakness, Leg muscle stiffness)

      HPOsFreeText: At 6 months head lag during pull to sit was noted, Had predominant overall flexion position of lower extremities with a tendency towards hip flexion/abduction/external rotation, with lateral thigh grooves suggestive of bilateral IT band tightness, AIMS score was between 10th and 25th percentile for chronological age and 50th percentile for her corrected age adjusted for prematurity while GMFM score was 16.55%, ALT 37 U/L (Normal 5–40 U/L), AST 53 U/L (Normal 15–41 U/L), ALP 174 U/L (Normal 24–170 U/L)

      CaseNotHPOs: HP:0003236, HP:0001712, HP:0001290 (Increased serum CK, Left ventricular hypertrophy, Decreased muscle tone)

      NotHPOsFreeText: Other evaluations including pulmonary, speech, and swallow were normal

    6. Patient 6

      Case6: Male, Caucasian, United States, 1 month onset, 6 months diagnosis, 8 months report

      CasePresentingHPOs: HP:0003236, HP:0001655, HP:0003701, HP:0006589, HP:0003093, (Increased serum CK, Patent foramen ovale, Proximal muscle weakness, Flaring of lower rib cage, Limited hip extension,

      HPOsFreeText: HyperCKemia was noticed in the first month (438 U/L; Normal 60–305) but normalized spontaneously by age 6 months, flexion/abduction/external rotation positioning of lower extremities and with bilateral IT band tightness was revealed at the same time, also had decreased active use of abdominal oblique muscles with a lack of active trunk rotation, Decreased active use of lower abdominal muscles with inability to achieve a posterior pelvic tilt in supine, AIMS score was at 1st percentile for age and GMFM was at 12.3%, ALT 30 U/L (Normal 5–40 U/L), AST 90 U/L (Normal 15–41 U/L), ALP 249 U/L (Normal 24–170 U/L), Urinary Glc4 2.6 mmol/mol creatinine (Normal ≤8.3 mmol/mol creatinine)

      CaseNotHPOs: HP:0001712, HP:0001290 (Left ventricular hypertrophy, Decreased muscle tone)

      NotHPOsFreeText: Other evaluations including cardiac, pulmonary, speech, and swallow were normal

    1. one confirmed LOPD patient

      Case1: Female, 55 years report, 25 years onset, Brazil, African

      CasePresentingHPOs: HP:0003325, HP:0003236, HP:0003148, HP:0100284, HP:0011807, HP:0003326, HP:0008994, HP:0002527, HP:0003551, HP:0002015, HP:0000822, HP:0000819, HP:0003119, HP:0003707, HP:0003391, HP:0003327, HP:0001315, HP:0002515, HP:0010546 (Limb-girlde muscle weakness, Increased serum CK, Elevated serum acid phosphatase, EMG: myotonic discharges, Type 1 muscle fiber atrophy, Myalgia, Proximal muscle weakness in lower limbs, Falls, Difficulty climbing stairs, Dysphagia, Hypertension, Diabetes mellitus, Dyslipidemia, Calf muscle pseudohypertrophy, Gowers sign, Axial muscle weakness, Reduced deep tendon reflexes, Waddling gait, Muscle fibrillation)

      HPOsFreeText: Serum CK 1467 U/L (normal: ≤ 200U/L), NaG/AaGIA ratio 40.4, %INH 87.2, GAA activity 4.2% from dried blood spot, Falls occurring mainly when walking for long distances, Normal Mini-Mental State Examination score (27/30), Mild symmetrical weakness in proximal muscles in the lower limbs (Medical Research Council grade 4), Needle electromyography revealed motor unit potentials with low amplitude and short duration in the iliopsoas muscle associated with fibrillation and short myotonic discharge potentials in lumbar paraspinal muscles

      CaseNotHPOs: HP:0001270 (Motor delay)

      NotHPOsFreeText: Muscle biopsy with the absence of vacuolar myopathy

      CaseAddInfo: Late-Onset Pompe Disease, One sister diagnosed with LOPD based on low GAA activity and shared genetic variants but no other known relatives with the condition

    1. 3

      Case3: Male, 19 years report, Italy

      CasePresentingHPOs: HP:0003551 (Difficulty climbing stairs)

      HPOsFreeText: Height is 1.78 m, Weight is 60 kg, BMI is 18.9 kg/cm2, 7 years on ERT, Forced Vital Capacity at 107%

      CaseNotHPOs: HP:0002098 (Respiratory distress)

      NotHPOsFreeText: Nocturnal non-invasive ventilation

      CaseAddInfo: Late Onset Pompe Disease

    2. 1

      Case1: Female, 46 years report, Italy

      CasePresentingHPOs: HP:0003551 (Difficulty climbing stairs)

      HPOsFreeText: Height is 1.64 m, Weight is 50 kg, BMI is 18.6 kg/cm2, 2 years on ERT, Forced Vital Capacity at 108%

      CaseNotHPOs: HP:0002098 (Respiratory distress)

      NotHPOsFreeText: Nocturnal non-invasive ventilation

      CaseAddInfo: Late Onset Pompe Disease

    1. II

      CaseII: Adult onset, 71 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003326, HP:0003236, HP:0003198 (Proximal muscle weakness, Myalgia, Increased serum CK, Myopathy)

      HPOsFreeText: Plasma CK 5–10× Normal, GAA activity from dried blood spot: 0%, 6-Minute Walking Test: 40 min, Forced Vital Capacity Seated: 850 (22%)

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    2. 1

      CaseV,1: Adolescent onset, 42 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003236, HP:0003388, HP:0003326 (Proximal muscle weakness, Increased serum CK, Easy fatigability, Myalgia)

      HPOsFreeText: Plasma CK 5-10× Normal, Vacuoles in histology, 6-Minute Walking Test: 135 min, Forced Vital Capacity Seated: 950 (20%), GAA activity from dried blood spot: 0.20%

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    3. 3

      CaseV,3: Child onset, 45 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003236 (Proximal muscle weakness, Increased serum CK)

      HPOsFreeText: Plasma CK 2.5-5× Normal, GAA activity from dried blood spot: 0.08%, 6-Minute Walking Test: 566 min

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    4. III

      CaseIII: Adult onset, 63 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003388, HP:0003236, HP:0003198, HP:0002460, HP:0002015 (Proximal muscle weakness, Easy fatigability, Increased serum CK, Myopathy, Distal muscle weakness, Dysphagia)

      HPOsFreeText: Plasma CK 2.5–5× Normal, GAA activity from muscle: 11.7%

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    5. I

      CaseI: Early adult onset, 49 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003388, HP:0003236, HP:0003198 (Proximal muscle weakness, Easy fatigability, Increased serum CK, Myopathy)

      HPOsFreeText: Plasma CK 5–10× Normal, GAA activity from lymphocytes: 14.2%

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    6. 2

      CaseV,2: Adult onset, 33 years diagnosis

      CasePresentingHPOs: HP:0003701, HP:0003236, HP:0003388 (Proximal muscle weakness, Increased serum CK, Easy fatigability)

      HPOsFreeText: Plasma CK 5-10× Normal, 6-Minute Walking Test: 566 min, Forced Vital Capacity Seated: 3000 (90%), GAA activity from dried blood spot: 0.20%

      CaseNotHPOs: HP:0002795 (Abnormal respiration)

      CaseAddInfo: Late-Onset Pompe Disease

    1. 9

      Case9: Male, 40 years onset, 45 years diagnosis, 74 years report, France

      CasePresentingHPOs: HP:0002540, HP:0002878, HP:0004887 (Inability to walk, Respiratory failure, Respiratory failure requiring assisted ventilation)

      HPOsFreeText: Lost ambulation at 50 years, Started invasive ventilation at 67 years, Started ERT given every other week at a dose of 20 mg/kg at 70 years for 43 months, Peak Anti-rhGAA antibodies at 1:409,600, Time off ventilation stayed constant at 0 min, Total Motor Function Measure from 29 to 26, 6MWT stayed constant at 0 meters

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: No adverse reaction to ERT was recorded

      CaseAddInfo: Late Onset Pompe Disease

    2. 12

      Case12: Male, 35 years onset, 50 years diagnosis, 61 years report, France

      CasePresentingHPOs: HP:0002540, HP:0002878, HP:0004887 (Inability to walk, Respiratory failure, Respiratory failure requiring assisted ventilation)

      HPOsFreeText: Lost ambulation at 48 years, Started invasive ventilation at 35 years, Started ERT given every other week at a dose of 20 mg/kg at 56 years for 49 months, Peak Anti-rhGAA antibodies at 1:1600, FVC at 0 (L / % expected), MIP at 22 (cm H2O), MEP at 28 (cm H2O), Time off ventilation stayed constant at 0 min, 6MWT stayed constant at 0 meters

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: No adverse reaction to ERT was recorded

      CaseAddInfo: Late Onset Pompe Disease

    3. 3

      Case3: Male, 28 years onset, 30 years diagnosis, 69 years report, France

      CasePresentingHPOs: HP:0002540, HP:0002878, HP:0004887, HP:0002093 (Inability to walk, Respiratory failure, Respiratory failure requiring assisted ventilation, Respiratory insufficency)

      HPOsFreeText: Lost ambulation at 58 years, Started invasive ventilation at 28 years, Started ERT given every other week at a dose of 20 mg/kg at 68 years for 11 months, Peak Anti-rhGAA antibodies at 1:1600, FVC at 0.45/13 (L / % expected), MIP at 17 (cm H2O), MEP at 29 (cm H2O), Time off ventilation stayed constant at 0, Total Motor Function Measure from 31 to 27

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: No adverse reaction to ERT was recorded

      CaseAddInfo: Late Onset Pompe Disease, Patient died before publication

    1. 62-year-old man

      Case1: Male, 62 years report

      CasePresentingHPOs: HP:0002091, HP:0002878, HP:0003701, HP:0040047, HP:0002098, HP:0100786, HP:0006510, HP:0005978, HP:0000822, HP:0003124, HP:0001677, HP:0003236, HP:0004324, HP:0002329, HP:0030207, HP:0002098, HP:0040047, HP:0100750, HP:0002097, HP:0007269, HP:0040046 (Restrictive lung disease, Respiratory failure, Proximal muscle weakness, Abnormality of the right hemidiaphragm, Shortness of breath, Hypersomnia, Chronic obstructive pulmonary disease, Diabetes mellitus Type II, Hypertension, Hypercholesterolemia, Coronary artery disease, Elevated serum creatine kinase, Increased body weight, Drowsiness, Paradoxical respiration, Respiratory distress, Abnormality of the right hemidiaphragm, Atelectasis, Emphysema, Spinal muscular atrophy, Abnormality of the left hemidiaphragm)

      HPOsFreeText: Hypercapnic respiratory failure, Chronic phrenic neuropathy bilaterally, Long history of apparently idiopathic right hemidiaphragm paralysis, Underwent muscle biopsy and electromyography, both of which showed nonspecific myopathic features associated with mild denervation, On presentation, the patient's vital signs were a temperature of 36.5 °C (97.7 °F); heart rate, 94 beats/minute; blood pressure, 104/70 mm Hg; respiratory rate, 22 breaths/minute; oxygen saturation, 90% when receiving 2 L of supplemental oxygen per minute; and body mass index, 29.9 kg/m2, Decreased air entry bilaterally, Laboratory values were: Hemoglobin, 120 g/L; platelets, 279 × 109/L; white blood cells, 7.7 × 109/L; sodium, 140 mmol/L; potassium, 5.1 mmol/L; bicarbonate, 40 mmol/L; serum urea nitrogen, 3.6 mmol/L; creatinine, 70.7 μmol/L; and calcium, 2.48 mmol/L, Fatty atrophy of rotator cuff musculature, Tests for resting room-air arterial blood gases showed a pH of 7.29; PCO2, 89.4 mm Hg; PO2, 67.6 mm Hg; and serum bicarbonate, 43 mmol/L, Right diaphragm paralysis, Electromyography showed complete absence of phrenic compound muscle action potentials bilaterally. No activation of motor unit potentials was seen within the diaphragm, either with respiration or with volitional effort. Ultrasonography showed that the left hemidiaphragm was hyperechoic, 0.14 cm thick at functional residual capacity (FRC), with a thickening ratio of 1.1 (the thickening ratio is thickness at total lung capacity/thickness at FRC). The right hemidiaphragm was hyperechoic, 0.15 cm thick at FRC, with thickening ratio of 0.9. (Normal thickness is >0.15 cm, normal thickening ratio is >1.2.) The aldolase concentration was slightly increased at 9 U/L (reference level, <7.7 U/L). To complete the evaluation for rarer causes of diaphragmatic dysfunction, neurology services requested testing for inherited neuropathies. Three weeks later, the patient's serum GAA level was 1.0 nmol/mL/hour (reference level, >7.4 nmol/mL/hour)

      CaseNotHPOs: HP:0003549 (Abnormality of connective tissue)

      NotHPOsFreeText: The following tests were within reference range: creatine kinase, thyroid function tests, erythrocyte sedimentation rate, serum and protein electrophoresis, antinuclear antibody profile, and anti-Jo antibodies

      CaseAddInfo: Ex-Smoker with 40–80 pack-years of smoking, Medications at presentation to facility included aspirin, clopidogrel, simvastatin, diltiazem, sitagliptin, metformin, budesonide and formoterol inhaler, tiotropium bromide inhaler, and albuterol inhaler

    1. 1

      Case1: Female, 12 years report, 3 years onset, 12 years diagnosis

      CasePresentingHPOs: HP:0003325, HP:0002093, HP:0002650 (Limb-girdle muscle weakness, Respiratory insufficiency, Scoliosis)

      HPOsFreeText: 730 CK (U/L), Normal Heart, 0 GAA activity (µmol/L/h), Showed respiratory involvement and required nocturnal non-invasive ventilation, An ambulant patient with 284 m six minute walk distance at the time of diagnosis

      CaseNotHPOs: HP:0003457, HP:0001627 (EMG abnormality, Abnormality of the heart)

      NotHPOsFreeText: Muscle weakness confined to limb-girdle muscles

    1. 4

      Case4: 0.5 years diagnosis, Germany

      CasePresentingHPOs: HP:0031185, HP:0001635, HP:0001252, HP:0001324, HP:0003236, HP:0001639 (Increased NT-proBNP level, Cardiac failure, Muscular hypotonia, Muscle weakness, Increased serum CK, Hypertrophic cardiomyopathy)

      HPOsFreeText: 3924 BNP (pg/ml), 7.68 IVS (d) z score, 6.42 IVS (s) z score, Heart Failure at NYHA Class 3

      NotHPOsFreeText: No left-ventricular outflow tract obstruction

      CaseAddInfo: Infantile-Onset Pompe Disease

    1. 1117

      Case1117: Male, 35 years onset, Welsh/English, Caucasian

      CasePresentingHPOs: HP:0003560, HP:0005110 (Muscular dystrophy, Atrial fibrillation)

      HPOsFreeText: 1,000 –2000's CK level, Immunohistochemistry: dystrophin, sarcoglycans, merosin

      CaseNotHPOs: HP:0009051, HP:0002540 (Increased muscle glycogen content, Non-ambulatory)

    1. Patient Number 3

      Case3: Male, 35 years report, 5 years onset, Algeria, African

      CasePresentingHPOs: HP:0003323, HP:0003749, HP:0002355, HP:0007340, HP:0008956, HP:0003484, HP:0003236, HP:0003198 (Progressive muscle weakness, Pelvic girdle muscle weakness, Difficulty walking, Lower limb muscle weakness, Proximal lower limb amyotrophy, Upper limb muscle weakness, Increased serum CK, Myopathy)

      HPOsFreeText: At grade 3 of Vignos and Walton scales, CK rate was 5 times the normal value and AST and ALT were normal, EMG was compatible with a myopathic disorder, GAA activity measured in leukocytes was significantly decreased

      CaseNotHPOs: HP:0003115, HP:0003116, HP:0001270, HP:0001290, HP:0002240, HP:0001640, HP:0005952, HP:0002540 (Abnormal ECG, Abnormal echocardiography, Motor delay, Generalized hypotonia, Hepatomegaly, Cardiomegaly, Decreased pulmonary function, Non-ambulatory)

    1. 15

      Patient15: Male, 21 years report, 2 years onset

      CasePresentingHPOs: N/A

      HPOsFreeText: GAA activity 4.7% from a dried blood spot

      CaseNotHPOs: HP:0002098, HP:0001324, HP:0001640, HP:0002240 (Respiratory distress, Muscle weakness, Cardiomegaly, Hepatomegaly)

      NotHPOsFreeText: No wheelchair needed, Respiratory Assistance not needed

      CaseAddInfo: LOPD

    1. The affected patient

      Case1: Male, French-Canadian, 18 years onset, 54 years diagnosis and report

      CasePresentingHPOs: HP:0008994, HP:0000822, HP:0003119, HP:0004398, HP:0007185, HP:0009109, HP:0002094, HP:0012764, HP:0002098 (Proximal muscle weakness in lower limbs, High blood pressure, dyslipidemia, Peptic ulcer, Loss of consciousness, Denervation of the diaphragm, Dyspnea, Orthopnea, Shortness of breath)

      HPOsFreeText: Dependent on continuous positive airway pressure or bilevel positive airway pressure when he is lying flat or sleeping because of previous intubation and tracheostomy, GAA activity measured from dried blood spot was 0.87 pmol/h/punch (Normal 4.96 - 27.3)

      CaseAddInfo: Late Onset Pompe Disease, The patient’s mother had six miscarriages and died at age 75 of lung cancer and his father died of cardiac problems in his early sixties, It appears that no other family members, including his parents and two siblings, were affected, patient had a previous appendectomy, He has no allergies, stopped smoking in 2002, and denied any alcohol or drug use

    1. 10

      Case9: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0005542

      (Prolonged clotting time)

      CaseHPOFreeText: Bleeding time greater than 20 minutes and hematocrit of 38.1%

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1392A>G (p.Pro464Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500273575

      gnomAD: https://gnomad.broadinstitute.org/variant/17-42458248-T-C

    1. RL

      Case4: Patient RL

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    2. ProSsyl

      Case11: Patient Ssyl

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGB3

      Variant: NM_000212.2:c.1955A>T (p.His652Leu)

      LegacyVariant: (p.His626Leu)

      ClinVar: N/A

      CAiD: CA400032927

      gnomAD: N/A

    1. Supplementary Table S1 & S2 Proband and Variant Information:

      Case20: GT23, Male, 19, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000225, HP:0000421

      (Easy bruising, gingival bleeding, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.1031A>C (p.Tyr344Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025814

      gnomAD: N/A

    2. Supplementary Table S1 & S2 Proband and Variant Information:

      Case6: GT7, Female, 19, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: 1 brother, that is all the information Supp table S1 gives us

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978 and HP:0000421

      (Easy bruising and epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <10-15% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent ADP but some response with other agonists (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.187C>T (p.Arg63Cys) and NM_000212.2:c.505C>T (p.Arg169Ter)

      LegacyVariant: N/A

      ClinVar: 631774

      CAiD: CA8622892 and CA291224658

      gnomAD: MAF in the East Asian population is 0.00005012 http://gnomad.broadinstitute.org/variant/17-45360741-C-T

    3. Supplementary Table S1 & S2 Proband and Variant Information:

      Case9: GT10, Male, 45, French and Italian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild lifelong bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed 30-50% variant expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Residual platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1440-13_1440-1del (p.Arg480Serfs*106) and NM_000419.3:c.3077G>A (p.Arg1026Gln)

      LegacyVariant: N/A

      ClinVar: 50232

      CAiD: CA913184940 and CA10575572

      gnomAD: MAF in the European (non-Finnish) population 0.00006482 http://gnomad.broadinstitute.org/variant/17-45363676-T-C and MAF in the European (non-Finnish) population is 0.000008801 http://gnomad.broadinstitute.org/variant/17-42449775-C-T

    4. Supplementary Table S1 & S2 Proband and Variant Information:

      Case10: GT11, Female, 54, French and German

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132

      (Epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: Spontaneous bruising

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed 10-15% variant expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His) and NM_000419.3:c.1234G>A (p.Gly412Arg)

      LegacyVariant: N/A

      ClinVar: 2896 and 381748

      CAiD: CA115839 and CA8603182

      gnomAD: MAF in the Latino population is 0.0001453 http://gnomad.broadinstitute.org/variant/17-42458406-C-T

    1. Inhibition of Platelet Aggregation byAbciximab but Not by Aspirin Can BeDetected by a New Point-of-Care Test, the Hemostatus

      PMID: 10418797

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions a Glanzmann thrombasthenia patient; however, there is no mention of variants in ITGA2B and/or ITGB3; therefore, there is insufficient evidence

      PreviouslyPublished: The GT patient in this article has been previously published in this PMID: 2180491

    1. 1CabGT-1

      Case1: (Proband CabGT-1) Male, age not specified, China

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Surface expression detected by flow cytometry showed <5% GPIIb and <5% GPIIIa

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.531T>A (p.Cys177Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290955739

      gnomAD N/A

    2. 7CabGT-7

      Case7: (Proband CabGT-7) Female, age not specified, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% GPIIb and 11% GPIIIa surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: The first variant was found to be: NM_000419.3:c.1563T>A (p.Cys521Ter) and they did not find the second mutation

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950094

      gnomAD N/A

    3. 3CabGT-3

      Case3: (Proband CabGT-3), Male, age not specified, European Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: N/A

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.1214T>C (p.Ile405Thr) and c.1442-13_1442-1del, which is not showing up in CAR (Unregistered Variant?)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950815 (p.Ile405Thr)

      gnomAD N/A

    1. Supplementary Table S1:

      Case41: GT48, French, gender and age not specified here at this time

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.1094A>G (p.Asn365Ser) and NM_000212.2:c.1522del (p.Gln508SerfsTer161)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400026292 and CA772541579

      gnomAD: N/A

    2. Supplementary Table S1:

      Case23: GT26, French, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His)

      LegacyVariant: N/A

      ClinVar: 2896

      CAiD: CA115839

      gnomAD: N/A

    1. F1P1

      Case1: Patient F1P1, Male, 11 years old, Tunisian

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Table 1 states there is a family history of bleeding (we have minimal to no specific info on this)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0000978

      (Gingival bleeding, easy bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: GT diagnosis was based on absent platelet aggregation induced by ADP, collagen, and TRAP and subnormal or cyclical ristocetin induced agglutination

      CasePreviousTesting: Using PCR they successfully amplified 20 DNA fragments for the ITGA2B gene (covering more than 48% of the ITGA2B gene constituting 30 exons) and15 DNA fragments of theITGB3gene (covering 15 exons)

      Gene: ITGB3

      Variant: NM_000212.2:c.176T>C (p.Leu59Pro) and NM_000212.2:c.1143A>C (p.Val381Val) and NM_000212.2:c.1545G>A (p.Arg515Arg) and the other variant stated here is g.41037G>C which I am marking as an Unknown Variant-- biocurator should look at this and determine variant

      LegacyVariant: N/A

      ClinVar: 13558 (p.Leu59Pro), 255535 (p.Val381Val), 255537 (p.Arg515Arg)

      CAiD: CA123235 (p.Leu59Pro), CA8623175 (p.Val381Val), CA8623284 (p.Arg515Arg)

      gnomAD: MAF in the Ashkenazi Jewish population is 0.1565 https://gnomad.broadinstitute.org/variant/17-45360730-T-C for (p.Leu59Pro) and MAF in the East Asian population is 0.5857 https://gnomad.broadinstitute.org/variant/17-45368337-A-C for (p.Val381Val) and MAF in the East Asian population for (p.Arg515Arg) is 0.3455 https://gnomad.broadinstitute.org/variant/17-45369789-G-A

    1. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor–independent thrombin generation

      PMID: 12411291

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      NoEvidence: This article does not mention GT probands with variants in ITGA2B and/or ITGB3 therefore there is no evdience; however, there may be potenetial experimental assay information

    1. Interactionofhumanplateletswithlamininandidentificationofthe67kDalamininreceptoronplatelets

      PMID: 1826081

      Gene: ITGA2B and ITGB3 (we are noting these gene names even though there is no evidence for GT in this article, because we are curating for these genes-- CThaxton advised it would be a good idea to always note down Genes and HGNC)

      HGNC: 6138 and 6156

      NoEvidence: This article does not mention Glanzmann thrombasthenia patients/probands with variants in ITGA2B and/or ITGB3; therefore, there is no evidence to report. The studies performed in this article were undertaken to characterize the interaction of platelets with laminin.

    1. 6

      Case6: Female, Iraq, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132, HP:0031364

      (Epistaxis, gingival bleeding, menorrhagia, ecchymosis)

      CaseHPOFreeText: Post-partum bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del (p.Asp677Glufs)

      LegacyVariant: (p.Asp651Glufs*3)

      ClinVar: N/A

      CAiD: CA915940605

      gnomAD: N/A

    1. M/10

      Case2: Male, 10 years old, Andra Pradesh India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0002239, HP:0000225

      (Epistaxis, ecchymosis, GI bleeding, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.475G>A (p.Gly159Ser)

      LegacyVariant: (p.Gly128Ser)

      ClinVar: N/A

      CAiD: CA8603454

      gnomAD: MAF in the South Asian population is 0.00003267 https://gnomad.broadinstitute.org/variant/17-42463018-C-T

    2. M/13

      Case1: Male, 13 years old, Andra Pradesh India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0006298, HP:0000421, HP:0000967, HP:0002239, HP:0000225

      (Prolonged bleeding after dental extraction, epistaxis, petechiae, GI bleeding, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.48G>A (p.Trp16Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399807046

      gnomAD: N/A

    1. .

      Case4: No gender, age, or ethnicity provided. Patient followed in Germany

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.1717T>C (p.Cys573Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032387

      gnomAD: N/A

    1. Successful Management of Acute Catastrophic Juvenile Vaginal Bleeding in Glanzmann's Thromboasthenia by Uterine Tamponade: A Case Report and Review of The Literature

      PMID: 22928124

      Genes: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article reports a case of acute catastrophic vaginal bleeding in a girl, who was diagnosed with GT and responded to uterine tamponade for acute control of vaginal bleeding; however, no variants in ITGA2B and/or ITGB3 are mentioned in this article therefore we have insufficient evidence

    1. The French patient who is the object of this study is now an elderly male with a lifelong but mild bleeding disorder

      Case1: Male, French, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A "Has no surviving close relatives"

      ParentalGenotype:

      CasePresentingHPOs: HP:0002239 (GI bleeding)

      CaseHPOFreeText: Hemorrhage

      CaseNotHPOs: HP:0000421, HP:0000225

      (Epistaxis, gingival bleeding)

      CaseNotHPOsFreeText: N/A

      ProteinExpression:

      PlateletAggregation: Total lack of platelet aggregation in response to physiologic agonists and also defective clot retraction

      CasePreviousTesting: Direct sequencing of all exons and splice sites of ITGA2B was performed and sequencing of the 15 exons, splice sites, and promoter of ITGB3 was also performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1413C>G (p.Tyr471Ter) and NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950376 and CA399801310

      gnomAD: MAF in European (non-Finnish) population 0.000008791 http://gnomad.broadinstitute.org/variant/17-42457994-G-C and MAF in the Latino population is 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    1. FLOW CYTOMETRIC ANALYSIS OF PLATELET SURFACE GLYCOPROTEINS IN THE DIAGNOSIS OF BERNARD-SOULIER SYNDROME

      PMID: 9021812

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      NoEvidence: This article does not mention Glanzmann thrombasthenia patients/probands with variants in ITGA2B and/or ITGB3; therefore, there is no evidence to report

    1. VISUALIZATION OF PLATELET GLYCOPROTEINS Ib AND IIIa BY IMMUNOENZYMATIC STAIN USING AVIDIN-BIOTIN PEROXIDASE COMPLE

      PMID: 1788826

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      NoEvidence: This article does not mention Glanzmann thrombasthenia probands with variants in ITGA2B and/or ITGB3; therefore, there is no evidence

    1. M8

      Case16: (M8) Male, 47 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    1. Platelet Glycoprotein IIb/IIIa Receptors and Glanzmann’s Thrombasthenia Deborah L. French and Uri SeligsohnFrom the Mount Sinai School of Medicine (D.L.F.), New York, NY, and The Chaim Sheba Medical Center (U.S.), Tel-Hashomer, Israel.

      PMID: 10712380

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This review mentions many variants in ITGA2B and ITGB3; however, there are no probands to tie these variants to therefore there is insufficient evidence

    1. Supplementary Tables 1 and 2 combined information:

      Case20a: GT20a, Male, 30 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Family information available in Table1 (brother of GT20b)

      ParentalGenotype: Parents are consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000225

      (Gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399801310

      gnomAD: MAF in Latino population: 0.00003983 https://gnomad.broadinstitute.org/variant/17-42456075-G-A

    1. Supplemental Table S1:

      Cases6-11: Males and Females from India/Pakistan, ages not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Moderate to severe bleeding tendency in these patients

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: <5% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A (p.Arg551Gln)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in the South Asian population is 0.00006536 https://gnomad.broadinstitute.org/variant/17-42457470-C-T

      PreviouslyPublished: PMID: 19172520 and 26896847

    2. Supplemental Table S1:

      Cases 13-18: Males and Females, from Sweden, France and Germany and other places, ages are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Moderate to severe bleeding when data was available

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 5%/<5% when homozygous αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1787T>C (p.Ile596Thr)

      LegacyVariant: N/A

      ClinVar: 2900

      CAiD: CA115846

      gnomAD: MAF in the European non finnish pop is 0.0001325 https://gnomad.broadinstitute.org/variant/17-42457148-A-G

      PreviouslyPublished: PMID: 9215749, 9734640, 20020534, 22513797, 25373348

    1. The proband, a 35-year old woman from southern Italy,

      Case1: Female, 35 years old, Italian

      DiseaseAssertion: Macrothromocytopenia

      FamilyInfo: See Supp. Fig S1 for pedigree

      ParentalGenotype: See Supp. Fig S1 for pedigree

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Life-long moderate to severe bleeding, mainly mucocutaneous

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: No abnormalities in blood clotting

      ProteinExpression: Flow cytometry showed mild reduction of surface αIb β3

      PlateletAggregation: Impaired platelet aggregation to physiological agonists but not to ristocetin,

      CasePreviousTesting: ITGA2B and ITGB3 were amplified and sequenced

      Gene: ITBG3

      Variant: NM_000212.2:c.2134+1G>C

      LegacyVariant: N/A

      ClinVar: 50228

      CAiD: CA143711

      gnomAD: N/A

    1. boy

      Case#: Kuijers_1993_NAIT boy_male_>1 y.o.

      DiseaseAssertion:

      FamilyInfo: All members of this large family were healthy and none had a history of a bleeding tendency or a tendency for thrombosis and/or embolism. There was no previous case of NAIT in the family. Routine blood counts were normal. From the segregation pattern in the family, it can be concluded that the Mo antigen is inherited as an autosomal dominant allele

      ParentalGenotype: One affect (likely homozygous) and one unaffected (not carrying)

      CasePresentingHPOs: HP:0000967 Petechiae, HP:0007420 Spontaneous hematomas,

      PlateletAggregation:

      CaseHPOFreeText: hemoglobin (Hb) count of 13.1 mmol/L, hematocrit (Ht) 0.61, leukocyte count 36.6 × 106/L (3 hours postpartum), Gastrointestinal tract bleedings (2 days postpartum). s treated with high-dose intravenous Ig (IVIg) (0.4 g/kg) for 3 days. The platelet count stabilized and started to increase slowly to 46 × 109 in the following weeks

      CaseNotHPOs:

      CaseNotHPOFreeText:

      ProteinExpression: Western blotting showed that the antigen resides on platelet glycoprotein IIIa

      CasePreviousTesting:

      Method: PCR coding region

      PreviouslyPublished:

      Gene: ITGB3

      Variant: NM_000212.3:c. _C>G (C → G at base 1267 was observed. This C → G mutation changes a CCC codon for proline into a GCC that codes for alanine at amino acid 407 of the mature GP IIIa DNA.) (No other base-pair changes in the entire GP IIIa cDNA were noticed.)

      HGVS:

      ClinVar:

      CAID:

      gnomAD:

      Affected: 11

      Unaffected: 20

      Segregations: 11

      eLOD: 3.31

    1. B

      Case2: Patient ID B, Male, 16 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 asserts family information is provided; however, minimal information

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0004406, HP:0000225

      (Recurrent epsitaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify a;; coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>G (p.Leu214Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805518

      gnomAD: MAF in South Asian population 0.00003266 http://gnomad.broadinstitute.org/variant/17-42462561-A-C

    1. 40-year-old woman

      Case#: 40 yo, Female, W. Turkey

      DiseaseAssertion: Glanzmann Thrombasthenia

      FamilyInfo: Consanguineous (cousins).

      ParentalGenotype: Both carriers.

      CasePresentingHPOs: (HP:0007420) Spontaneous hematomas, (HP:0001892) Abnormal bleeding, (HP:0100608) Metrorrhagia, (HP:0001935) Microcytic anemia, (HP:0034263) Abnormal vaginal bleeding, (HP:0004944) Cerebral aneurysm,

      PlateletAggregation: Hypochromic anemia and a platelet count of 198 × 109/L (normal range 150–400 × 109/L). Platelet aggregometry showed no aggregation after stimulation with collagen (2 and 10 µg/mL), ADP (4 and 10 µmol/L), and epinephrine (8 µmol/L) (norm > 70%), and reduced (42%, Norm > 70%) agglutination after stimulation with ristocetin (1.2 mg/mL).

      CaseHPOFreeText: Received platelet concentrates multiple times as a young adult before dental surgery. Pregnancy, alloantibodies to glycoprotein αIIbβ3 were detected in the patient’s blood. emergency caesarean section was performed in another hospital. Because the patient developed severe bleeding problems, she received two red cell units, two pooled platelet concentrates, tranexamic acid, and desmopressin intraoperatively. Two drainages were placed. Three platelet concentrates were transfused in the following days, resulting in a first-time transfusion reaction. Emergency cesarean- endometrial coagulation, operative hysteroscopy.

      ProteinExpression: Flow cytometry showed the absence of expression of CD41 (integrin αIIbβ3) and severely impaired fibrinogen binding after ADP activation

      CasePreviousTesting: molecular genetic analysis was performed using a custom gene panel for inherited platelet disorders (Nextera Rapid Custom Enrichment, Illumina, San Diego, CA, USA) established in our department, followed by sequencing on a MiSeq (Illumina)

      Gene: ITGA2B

      HGVS: 6138

      ClinVar: Unregistered

      CAID: CA2261369696

      gnomAD: Absent

      Gene: ITGA2B

      HGVS: 6138

      ClinVar: Unregistered

      CAID: CA2261369696

      gnomAD: Absent

    1. 1

      Case1: Male, 3.5 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: (HP:0000421 Epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1286G>A (p.Asp396Asn)

      LegacyVariant: (p.Asp365Asn)

      ClinVar: N/A

      CAiD: CA399803675

      gnomAD: N/A

    1. Case 1

      Case#: Case 1, 35 yo Female

      DiseaseAssertion: Glanzmann thrombasthenia

      ParentalGenotype: Not provided

      CasePresentingHPOs: (HP:0031364, Ecchymosis) (HP:0034000, Tracheal hemorrhage)

      PlateletAggregation: Responded partially to tranexamic acid

      CaseHPOFreeText: intrauterine blood clots

      CaseNotHPOs:

      CaseNotHPOFreeText:

      ProteinExpression: Western blot, trace amounts of αIIb and residual expression of β3

      CasePreviousTesting: Molecular analysis

      PreviouslyPublished: Not provided

      Gene: ITGA2B

      HGVS: NM_000419.5:c.2095-19T>A

      ClinVar: 1691455 https://www.ncbi.nlm.nih.gov/clinvar/variation/1691455/

      CAID: CA915940312

      gnomAD: Absent

      Gene: ITGA2B

      HGVS: NM_000419.5:c.2770C>T

      ClinVar: 1691475 https://www.ncbi.nlm.nih.gov/clinvar/variation/1691475/

      CAID: CA399792054

      gnomAD: PopMax = 0.000002616 https://gnomad.broadinstitute.org/variant/17-44375069-G-A?dataset=gnomad_r4

    1. The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend

      PMID: 18840725

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      NoEvidence: This article is a review discussing the integrin αIIbβ3, there is no mention of probands with variants in ITGA2B and/or ITGB3

    1. GT-63

      Case51: (GT-63) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.558C>G (p.Tyr186Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805728

      gnomAD: N/A

    1. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia

      PMID: 18450741

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InusufficientEvidence: This article used a bifunctional bioengineered disintegrin/alkaline phosphatase hybrid protein ErAPv to evaluate 14 consecutive cases of Glanzmann thrombasthenia and 20 normal healthy controls. Thererefore, GT probands are mentioned; however, no specific variants in ITGA2B and/or ITBG3 have been mentioned in these patients

    1. TA

      Case12: Patient TA, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: His son is Patient TE

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B and ITGB3

      Variant: ITGA2B variant: NM_000419.3:c.3060G>A and ITGB3 variant: NM_000212.2:c.856G>A (p.Gly286Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500261104 and CA400020688

      gnomAD: MAF in the European (non-Finnish) population is 0.00001760 https://gnomad.broadinstitute.org/variant/17-45364514-G-A for the ITGB3 variant

    1. Patientstudies.

      Case1: Female, 14 years old, German

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Severe hemorrhage after tonsillectomy, bleeding after shedding off her deciduous teeth, prolonged cutaneous bleeding time > 20 minutes

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Flow cytometry revealed that the proband expressed only 7-10% of GPIIb-IIIa on the platelet surface

      PlateletAggregation: Absent aggregation in response to ADP, collagen, epinephrine, and arachidonic acid but normal platelet aggregation in response to ristocetin

      CasePreviousTesting: Sequence analysis of PCR amplifeid platelet GPIIb mRNA was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His)

      LegacyVariant: (p.Arg327His)

      ClinVar: 2896

      CAiD: CA115839

      gnomAD: N/A

    1. M4

      Case4: Patient M4, Male, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree It shows this patient is unaffected

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

  2. www.researchgate.net www.researchgate.net
    1. Patient 2

      Case2: Patient 2, Male, 4 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother is Patient 1

      ParentalGenotype: Mother and father revealed heterozygosity for c.1878G>C mutation. (Parents are consanguineous)

      CasePresentingHPOs: HP:0000967 (Petechiae)

      CaseHPOFreeText: Hematomas, prolonged in vitro bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed that there was 109 of GPIIb/IIIa expression for Patient 2

      PlateletAggregation: All patients' platelets showed severely reduced platelet aggregation after stimulation with collagen and ADP in contrast to the normal range (See Table 1). Stimulation with epinephrine and arachidonic acid also demonstrated decreased platelet aggregation. In contrast, ristocetin-induced platelet aggregation was borderline for Patient 2

      CasePreviousTesting: Sequenced ITGA2B and ITGB3 genes from one patient of each family (Patient 2 and 3) and Patient 1 and 4 were screened for the identified mutation in the corresponding family.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD: N/A